VANCOUVER, B.C., January 30, 2026— ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a corporate update and an outline of its strategic positioning within the rapidly emerging in vivo immune cell engineering and chimeric antigen receptor (CAR) space.
ME Therapeutics continues to focus its attention to scientifically validated cancer targets to develop a diverse pipeline of drug candidates to move into clinical testing. Our pipeline candidates include therapeutic mRNAs designed to promote an anti-cancer immune response in cancers such as microsatellite stable (MSS) metastatic colorectal cancer that is currently untreatable with immunotherapy. Our lead therapeutic mRNA activates an important, scientifically validated target called STING (Stimulator of Interferon Genes), specifically in the tumor microenvironment. In a preclinical colorectal cancer model, our STING activator leads to the specific recruitment of immune cells into the tumor and significantly reduces tumor growth. Importantly, our data suggests that a single dose of our STING activator can synergize with a PD-1 checkpoint inhibitor where the PD-1 inhibitor is ineffective on its own. This could mean that providing our STING activator may unlock the efficacy of checkpoint inhibitors in otherwise unresponsive tumors. In addition, we believe this candidate may solve some of the past roadblocks observed with drugs targeting STING through the targeted delivery into myeloid cells in the tumor microenvironment which could reduce systemic side effects.
The Company is also continuing to make significant progress advancing its in vivo CAR pipeline. Traditional CAR-T therapies (currently approved for blood cancers) rely on an ex vivo process. This requires harvesting a patient’s T-cells, shipping them to a lab, genetically modifying them, and shipping them back for re-infusion. While highly effective, this process is costly, slow, and complex. In vivo CAR therapy bypasses these logistical hurdles by delivering the genetic instructions directly into the patient. The patient’s body becomes the factory, engineering its own immune cells to fight cancer. This approach offers the potential for “off-the-shelf” availability, reduced costs, and broader accessibility. Recently, the investment community has recognized in vivo delivery as the next frontier in biotech and ME Therapeutics believes that targeting both myeloid cells and T cells with a single in vivo CAR may enhance efficacy of CAR therapy in solid tumors making it even more broadly applicable. Our pipeline includes an in vivo CAR using our recently licensed CD22 nanobody asset, a CAR targeting a validated protein expressed in the tumor microenvironment in most solid tumors, and a potentially universal CAR that may be used to target any cancer protein with existing antibodies. The Company has made progress optimizing its CAR constructs to be functional in both myeloid cells and T cells to potentially enhance efficacy in solid tumors by reprogramming both cell types. Testing has shown that our CARs function effectively for myeloid cell based killing of tumor cells and that the same CARs can lead to T cell activation. Our plan is to initiate in vivo testing of our optimized CARs using validated lipid nanoparticle (LNP) delivery systems in mouse cancer models in the coming weeks.
Finally, the Company has been exploring the possible use of its lead antibody candidate targeting G-CSF to overcome resistance to current VEGF-inhibitors as there has been renewed interest in VEGF as a target in immunotherapy due to the recent success of bi-specific antibodies targeting PD-1 and VEGF.
To unlock additional value for existing shareholders, ME Therapeutics is continuing to work with Luckosky Brookman LLP in pursuit of a potential listing on either the Nasdaq Capital Market or New York Stock Exchange American (NYSE) and has met with several specialized investment banks to potentially assist in the process. The Company continues to assess the necessary steps for uplisting and will work to meet the financial and regulatory requirements for approval. However, there is no guarantee that the Company will satisfy the criteria, that an application will be accepted or as to the timing for completion of any of these steps.
“The excitement we are starting to see in the market for immune reprograming in vivo is not just a trend—it is the necessary evolution of cancer care. By combining our deep expertise in the immune system with advanced LNP delivery from worldclass partners and validated targets such as CD22, ME Therapeutics is building a platform capable of reshaping the tumor microenvironment and democratizing cell therapy.” – Salim Dhanji, PhD, CEO.
About ME Therapeutics
Myeloid Enhancement (ME) Therapeutics is a publicly listed biotechnology company based in Vancouver discovering and developing novel immuno-oncology therapeutics that reprogram the tumour microenvironment to fight cancer. Our pipeline is aimed at enhancing immune recognition of cancer cells and overcoming immune suppression in the tumour microenvironment. For more information, please visit http://metherapeutics.com and the Company’s profile on SEDAR+ at http://www.sedarplus.ca.
Contacts
Company: Salim Dhanji, PhD, salim@metherapeutics.com, +1-236-516-7714
Media: Claire Piech, claire@magneticcomms.com, +1-604-698-6637
ON BEHALF OF THE BOARD
“Salim Dhanji”
Dr. Salim Dhanji, PhD
Chief Executive Officer and Director
